Association of the Metabolic Syndrome and Long-Term Renal Function in Kidney Donors

2011 ◽  
Vol 43 (5) ◽  
pp. 1601-1606 ◽  
Author(s):  
D. Cuevas-Ramos ◽  
P. Almeda-Valdés ◽  
M. Arvizu ◽  
J. Mata ◽  
L.E. Morales-Buenrostro ◽  
...  
2010 ◽  
pp. OR15-2-OR15-2
Author(s):  
D Cuevas-Ramos ◽  
P Almeda-Valdes ◽  
J Alberu ◽  
M Arvizu ◽  
J Mata ◽  
...  

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Kosuke Honda ◽  
Satoru Kuriyama ◽  
Kimiyoshi Ichida ◽  
Tomoko Nakano ◽  
Naoki Sugano ◽  
...  

Abstract Background Insulin-like growth factor-1 (IGF-1) acts on glucose and protein metabolism and human growth and also influences blood pressure and renal function. This study investigated whether the single-nucleotide polymorphism of IGF-1, rs35767, plays a role in metabolic syndrome indicators, including blood pressure, glucose metabolism, uric acid levels, and renal function. Methods In this retrospective longitudinal cohort study, blood samples from 1506 Japanese individuals were collected and used for genotyping for variant rs35767: T > C in the IGF-1 upstream promoter. Data were analyzed to identify associations between IGF-1 genotypes and patient biochemical parameters, including the components of metabolic syndrome and the long-term change in renal function. Results The cohort rs35767 genotypes included 650 CC carriers (43.2%), 687 TC carriers (45.6%), and 169 TT carriers (11.2%). Multiple regression analysis revealed no association between IGF-1 genotype and blood pressure, glycated hemoglobin level, and serum uric acid level. However, in females, blood pressure was negatively correlated with the TT genotype. Longitudinal observation revealed that the decline in eGFR over 10 years was greater in TT (− 18.51 ± 1.04 mL/min/1.73m2) than in CC carriers (− 16.38 ± 0.52 mL/min/1.73m2; P < 0.05). Conclusion The present study suggests that renal function declines faster in individuals with the TT genotype at the IGF-1 rs35767 locus than in those with the CC genotype, suggesting that the TT genotype is associated with the long-term chronological decline in renal function.


2011 ◽  
Vol 96 (5) ◽  
pp. 1271-1274 ◽  
Author(s):  
Miriam Hudecova ◽  
Jan Holte ◽  
Matts Olovsson ◽  
Anders Larsson ◽  
Christian Berne ◽  
...  

2002 ◽  
Vol 28 (4) ◽  
pp. 195-214 ◽  
Author(s):  
Janine Nuver ◽  
Andries J Smit ◽  
Aleida Postma ◽  
Dirk Th Sleijfer ◽  
Jourik A Gietema

2005 ◽  
Vol 162 (5) ◽  
pp. 438-447 ◽  
Author(s):  
Cynthia J. Girman ◽  
Jacqueline M. Dekker ◽  
Thomas Rhodes ◽  
Giel Nijpels ◽  
Coen D. A. Stehouwer ◽  
...  

1986 ◽  
Vol 105 (6) ◽  
pp. 975
Author(s):  
LAWRENCE J. SPRECHER
Keyword(s):  

Medicina ◽  
2019 ◽  
Vol 55 (8) ◽  
pp. 489
Author(s):  
Plotogea ◽  
Ilie ◽  
Sandru ◽  
Chiotoroiu ◽  
Bratu ◽  
...  

Liver transplantation (LT) is considered the curative treatment option for selected patients who suffer from end-stage or acute liver disease or hepatic malignancy (primary). After LT, patients should be carefully monitored for complications that may appear, partially due to immunosuppressive therapy, but not entirely. Cardiovascular diseases are frequently encountered in patients with LT, being responsible for high morbidity and mortality. Patients with underlying cardiovascular and metabolic pathologies are prone to complications after the transplant, but these complications can also appear de novo, mostly associated with immunosuppressants. Metabolic syndrome, defined by obesity, hypertension, dyslipidemia, and hyperglycemia, is diagnosed among LT recipients and is aggravated after LT, influencing the long-term survival. In this review, our purpose was to summarize the current knowledge regarding cardiovascular (CV) diseases and the metabolic syndrome associated with LT and to assess their impact on short and long-term morbidity and mortality.


2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Noelle Ma ◽  
Daniel B. Hardy

Epidemiological studies have suggested that metabolic programming begins during fetal life and adverse eventsin uteroare a critical factor in the etiology of chronic diseases and overall health. While the underlying molecular mechanisms linking impaired fetal development to these adult diseases are being elucidated, little is known about how we can intervene early in life to diminish the incidence and severity of these long-term diseases. This paper highlights the latest clinical and pharmaceutical studies addressing how dietary intervention in fetal and neonatal life may be able to prevent aspects of the metabolic syndrome associated with IUGR pregnancies.


Sign in / Sign up

Export Citation Format

Share Document